Research
Hormonal
GLP-1RAs appear to be safe and effective in patients with inflammatory bowel disease (IBD).
Healthcare providers can consider GLP-1RAs as a treatment option for IBD patients.
StrongSupportsmedium confidence
GLP-1RAs appear to be safe and effective in patients with IBD.
Why this rating
Based on a meta-analysis of observational studies.
Source
Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis
Noppachai Siranart et al. · Journal of Crohn s and Colitis · 2025
DOI 10.1093/ecco-jcc/jjaf193
Meta-analysisCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →